Pediatric Oncology, Tata Memorial Hospital, Mumbai, India.
Homi Bhabha National Institute, Mumbai, India.
Pediatr Blood Cancer. 2018 Oct;65(10):e27288. doi: 10.1002/pbc.27288. Epub 2018 Jun 12.
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an uncommon subtype of Hodgkin lymphoma (HL) with few published studies in children, entirely from North America and Europe. We analyzed clinical features and treatment outcome of pediatric NLPHL.
Children less than 18 years of age diagnosed after histopathology review to have NLPHL between June 1998 and August 2016 were retrospectively analyzed. Descriptive details of clinical presentation and treatment were collected, and outcomes analyzed using Kaplan-Meier survival analysis.
Of the 42 patients with a confirmed diagnosis of NLPHL during this period, there was complete information on 35. Median age was 11 years (range 6-16 years), male:female ratio was 4.8:1, there were 15, 11, 6, and 3 patients with Stage I, Stage II, Stage III, and Stage IV disease, respectively. Six patients had B symptoms, 10 had bulky disease, and 3 had bone marrow as well as extranodal involvement. Histology was typical NLPHL in 23 and variant in 12. Twenty-nine received chemotherapy, 10 with additional radiation, 3 patients with early stage disease received only radiotherapy and three others underwent complete node resection alone. Median follow-up was 55 months (range 7-165 months), 5 year event-free survival (EFS) was 83.3%, and overall survival 97.1%. Variant NLPHL histology was associated with higher incidence of unfavorable presentation and lower EFS.
NLPHL in India has an excellent outcome, despite a higher incidence of unfavorable presentations such as advanced stage disease, B symptoms, and bulky disease. Variant histology is an adverse prognostic factor.
结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)是一种罕见的霍奇金淋巴瘤(HL)亚型,在儿童中仅有少数来自北美和欧洲的研究报道。我们分析了儿童 NLPHL 的临床特征和治疗结果。
回顾性分析了 1998 年 6 月至 2016 年 8 月间经组织病理学复查诊断为 NLPHL 的年龄小于 18 岁的儿童患者。收集了临床表现和治疗的详细描述,并使用 Kaplan-Meier 生存分析评估了结果。
在此期间,共有 42 例患者被确诊为 NLPHL,其中有 35 例患者的信息完整。中位年龄为 11 岁(范围 6-16 岁),男:女比例为 4.8:1,分别有 15、11、6 和 3 例患者分期为Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期。6 例患者有 B 症状,10 例患者有巨大肿块,3 例患者骨髓和结外受累。23 例患者为典型 NLPHL,12 例为变异型。29 例患者接受了化疗,10 例患者加用了放疗,3 例早期患者仅接受了放疗,另外 3 例患者仅接受了完全淋巴结切除术。中位随访时间为 55 个月(范围 7-165 个月),5 年无事件生存率(EFS)为 83.3%,总生存率为 97.1%。变异型 NLPHL 组织学与不良表现(如晚期疾病、B 症状和巨大肿块)发生率较高和 EFS 较低相关。
尽管印度的 NLPHL 存在更多不良表现,如晚期疾病、B 症状和巨大肿块,但预后仍然良好。变异型组织学是一个不良预后因素。